Airsculpt Technologies, Inc. (AIRS)
NASDAQ:AIRS
Want to see AIRS full AI Analyst Report?
AIRS Stock Chart & Stats
$3.57
>-$0.01(-0.17%)
At close: 4:00 PM EST
$3.57
>-$0.01(-0.17%)
Day’s Range― - ―
52-Week Range$1.51 - $12.00
Previous CloseN/A
Volume69.34K
Average Volume (3M)1.05M
Market Cap
$324.51M
Enterprise Value$393.65M
Total Cash (Recent Filing)$16.69M
Total Debt (Recent Filing)$71.02M
Price to Earnings (P/E)―
Beta2.54
Next Earnings
Aug 07, 2026EPS Estimate
0.02Next Dividend Ex-DateN/A
Dividend YieldN/A
Share Statistics
EPS (TTM)-0.18
Shares Outstanding70,545,685
10 Day Avg. Volume629,231
30 Day Avg. Volume1,053,493
Financial Highlights & Ratios
PEG Ratio-0.29
Price to Book (P/B)1.36
Price to Sales (P/S)0.79
P/FCF Ratio172.97
Enterprise Value/Market Cap1.21
Enterprise Value/Revenue2.59
Enterprise Value/Gross Profit4.28
Enterprise Value/Ebitda91.06
Forecast
1Y Price Target
$4.50Price Target Upside26.05% Upside
Rating ConsensusHold
Number of Analyst Covering2
EPS Forecast (FY)-0.05
Revenue Forecast (FY)$153.35M
Bulls Say, Bears Say
Bulls Say
Proprietary Procedure And Integrated Clinic ModelAirSculpt is a proprietary, minimally invasive body-contouring procedure delivered in company-owned clinics. This vertical, brand-led model supports quality control, patient experience, cross-selling of services, and potential pricing power—durable advantages for patient retention and unit economics.
Improved Cash GenerationTransition to positive operating and free cash flow materially improves financial flexibility. Sustained cash generation reduces reliance on external financing, funds reinvestment in clinics and marketing, and provides a buffer to support operations through demand cycles over the next several quarters.
Reduced Leverage / De-risked Balance SheetMaterial improvement in leverage lowers solvency and refinancing risk and increases resilience to revenue volatility. A healthier debt position gives management more optionality for capex, selective expansion, or absorption of temporary downturns without immediate liquidity strain.
Bears Say
Ongoing Net Losses And Pressured ProfitabilityPersistent net losses and negative operating profit limit shareholder returns and constrain internal funding for growth. Even with modest positive EBITDA, the inability to convert to consistent operating profits undermines long-term return on capital and increases sensitivity to cost inflation or lower demand.
Stagnant Revenue GrowthNearly flat trailing revenue suggests limited market expansion or plateauing demand. For a clinic-based model with fixed-location costs, stagnant top-line growth hampers margin expansion from operating leverage and reduces the return dynamics of adding new centers over the medium term.
High Exposure To Consumer Discretionary SpendingRevenue depends on elective, out-of-pocket procedures, making business cyclical with consumer spending trends. In economic weakness patients can defer elective care, increasing revenue volatility and making long-term planning and predictable cash flows more difficult without geographic or product diversification.
Airsculpt Technologies News
AIRS FAQ
What was Airsculpt Technologies, Inc.’s price range in the past 12 months?
Airsculpt Technologies, Inc. lowest stock price was $1.51 and its highest was $12.00 in the past 12 months.
What is Airsculpt Technologies, Inc.’s market cap?
Airsculpt Technologies, Inc.’s market cap is $324.51M.
When is Airsculpt Technologies, Inc.’s upcoming earnings report date?
Airsculpt Technologies, Inc.’s upcoming earnings report date is Aug 07, 2026 which is in 42 days.
How were Airsculpt Technologies, Inc.’s earnings last quarter?
Airsculpt Technologies, Inc. released its earnings results on May 08, 2026. The company reported -$0.03 earnings per share for the quarter, missing the consensus estimate of N/A by -$0.03.
Is Airsculpt Technologies, Inc. overvalued?
According to Wall Street analysts Airsculpt Technologies, Inc.’s price is currently Undervalued.
Does Airsculpt Technologies, Inc. pay dividends?
Airsculpt Technologies, Inc. pays a Notavailable dividend of $0.41 which represents an annual dividend yield of N/A. See more information on Airsculpt Technologies, Inc. dividends here
What is Airsculpt Technologies, Inc.’s EPS estimate?
Airsculpt Technologies, Inc.’s EPS estimate is 0.02.
How many shares outstanding does Airsculpt Technologies, Inc. have?
Airsculpt Technologies, Inc. has 70,545,685 shares outstanding.
What happened to Airsculpt Technologies, Inc.’s price movement after its last earnings report?
Airsculpt Technologies, Inc. reported an EPS of -$0.03 in its last earnings report, missing expectations of N/A. Following the earnings report the stock price went up 11.561%.
Which hedge fund is a major shareholder of Airsculpt Technologies, Inc.?
Currently, no hedge funds are holding shares in AIRS
What is the TipRanks Smart Score and how is it calculated?
Smart Score combines eight research factors - such as analyst recommendations, hedge fund trends, and technical indicators - to measure a stock’s outlook. These signals are unified into a single score that reflects bullish or bearish momentum. See detailed methodology
Airsculpt Technologies Stock Smart Score
Neutral
1
2
3
4
5
6
7
8
9
10
Analyst Consensus
Hold
Average Price Target:
$4.50 (26.05% Upside)
$4.50 (26.05% Upside)
Blogger Sentiment
Neutral
AIRS Sentiment 50%
Sector Average ―
Sector Average ―
Hedge Fund Trend
Increased
By 573.0 Shares
Last Quarter.
Last Quarter.
Insider Transactions
Bought Shares
Worth $839.5K over
the Last 3 Months
the Last 3 Months
Technicals
SMA
Negative
20 days / 200 days
Momentum
-59.81%
12-Months-Change
Fundamentals
Return on Equity
-12.42%
Trailing 12-Months
Asset Growth
-5.54%
Trailing 12-Months
Company Description
Airsculpt Technologies, Inc.
AirSculpt Technologies, Inc., together with its subsidiaries, focuses on operating as a holding company for EBS Intermediate Parent LLC that provides body contouring procedure services in the United States, Canada, and the United Kingdom. The company offers AirSculpt, a body contouring treatment that removes fat and tightens skin while sculpting targeted areas of the body in a minimally invasive procedure. It also provides AirSculpt+, a procedure that permanently removes fat and tightens the skin with unparalleled precision and finesse; and AirSculpt Smooth, an advanced cellulite removal tool. In addition, it provides fat removal procedures across treatment areas, such as the stomach, back, and buttocks; and fat transfer procedures that transfers the patient’s own fat cells to enhance the buttocks, breasts, hips, aging hands, or other areas. Further, the company’s body contouring procedures include the Power BBL, a Brazilian butt lift procedure; the Up a Cup, a breast enhancement procedure; and the Hip Flip, an hourglass contouring procedure. Additionally, it operates various centers. AirSculpt Technologies, Inc. was founded in 2012 and is headquartered in Miami Beach, Florida.
AIRS Earnings Call
Q1 2026
0:00 / 0:00
Earnings Call Sentiment|Neutral
The call highlights a company in active turnaround: operational actions (cost savings, debt reduction, marketing enhancements) have produced Q4 margin expansion, improved same-store sales trends and early traction with new services (skin tightening and skin removal). However, material revenue declines in 2025, weaker full-year adjusted EBITDA versus 2024, a sharp drop in operating cash flow, modest year-end cash, supply risk for key equipment and a reporting control matter temper the progress. Management’s 2026 guidance is conservative and back‑end loaded, reflecting improving momentum but ongoing execution and liquidity risks.View all AIRS earnings summariesAIRS Stock 12 Month Forecast
Average Price Target
$4.50
▲(26.05% Upside)
Technical Analysis
AMN Healthcare Services
―
Community Health
―
Cross Country Healthcare
―
Healthcare Services
―
National Healthcare
―
Ownership Overview
48.20% Insiders
1.47% Mutual Funds
46.97% Other Institutional Investors
2.06% Public Companies and
Individual Investors